To earn CME related to this news article, click here. January 28, 2009 — Prolonged use, but not ever-use, of loop diuretics is linked to a higher fracture risk in postmenopausal women, according to ...

The use of loop diuretics does not appear to be associated with changes in bone mineral density, falls or fractures in postmenopausal women, according to a report in the January 26 issue of Archives ...

Medication also has beneficial effect on change in body weight across diuretic use categories. HealthDay News — Semaglutide reduces the need for loop diuretics and has positive effects on symptoms, ...

Add Yahoo as a preferred source to see more of our stories on Google. Research suggests that taking the blockbuster weight loss drug Wegovy (semaglutide) can help heart failure patients reduce their ...

Semaglutide reduces the need for loop diuretic use and dose, and has positive effects on symptoms, physical limitations, and body weight in patients with heart failure with preserved ejection fraction ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — A treatment strategy of torsemide vs. furosemide did not improve long-term clinical outcomes for ...

In a meta-analysis, researchers found no difference in all-cause mortality for intensive-care patients with fluid overload who were treated with loop diuretics, compared with those given a placebo or ...

Study finds no significant difference in hospitalization and death rates between patients who had a loop diuretic prescription at the time of peritoneal dialysis vs those who did not. Loop diuretic ...

Thirst outcomes were investigated among patients with stable heart failure (HF), due to the limited data available on this relationship and how it, along with fluid and sodium intake, influences ...

For patients with chronic heart failure (HF) who have persistent congestion despite high doses of oral loop diuretics, the right way to intensify diuretics in the outpatient setting may be narrowed, ...

SQ Innovation today announced that results of the SUBCUT HF II trial of its product Lasix® ONYU, will be presented at Heart Failure 2026, the annual congress of the Heart Failure Association (HFA) of ...